DeepMed Research

The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Healing Touch in Treating Fatigue in Women Undergoing Radiation Therapy for Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer
Depression
Fatigue

Interventions: Procedure: Bio-field energy therapy
Procedure: fatigue assessment and management
Procedure: psychosocial assessment and care
Procedure: quality-of-life assessment
Procedure: therapeutic touch

First Posted Date: 2007-12-17

Last Posted Date: 2012-09-06

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 44

Registration Number: NCT00574145

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: erlotinib
Drug: RAD001

First Posted Date: 2007-12-17

Last Posted Date: 2016-05-10

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 14

Registration Number: NCT00574366

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors

Phase 1

Terminated

Conditions: Gastrointestinal Stromal Tumor

Interventions: Drug: imatinib mesylate
Drug: sunitinib malate
Other: pharmacological study

First Posted Date: 2007-12-14

Last Posted Date: 2011-11-16

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 6

Registration Number: NCT00573404

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States

Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: bevacizumab
Drug: carboplatin
Drug: erlotinib hydrochloride
Drug: paclitaxel
Genetic: gene expression analysis
Genetic: protein expression analysis
Genetic: proteomic profiling
Other: laboratory biomarker analysis

First Posted Date: 2007-10-30

Last Posted Date: 2017-06-08

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 116

Registration Number: NCT00550537

Locations: 🇺🇸
University of Florida Shands Cancer Center, Gainesville, Florida, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 4 locations

Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC

Phase 1

Terminated

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: nab-paclitaxel
Radiation: Radiation therapy

First Posted Date: 2007-10-16

Last Posted Date: 2014-06-09

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 13

Registration Number: NCT00544648

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Purchase Cancer Group - Paducah, Paducah, Kentucky, United States

and more 3 locations

Family Quality of Life Among Families With a Member Who is a Cancer Patient

Completed

Conditions: Breast Cancer
Colorectal Cancer
Head and Neck Cancer
Lung Cancer
Prostate Cancer
Solid Tumor

Interventions: Other: questionnaire administration
Other: survey administration
Procedure: quality-of-life assessment

First Posted Date: 2007-10-16

Last Posted Date: 2012-09-10

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 366

Registration Number: NCT00544336

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States

Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: celecoxib
Drug: Docetaxel
Drug: pemetrexed disodium
Other: laboratory biomarker analysis

First Posted Date: 2007-08-27

Last Posted Date: 2017-03-20

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 23

Registration Number: NCT00520845

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States

Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin
Genetic: gene expression analysis
Genetic: polymorphism analysis
Genetic: protein expression analysis
Other: pharmacological study

First Posted Date: 2007-08-09

Last Posted Date: 2012-11-01

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 33

Registration Number: NCT00514020

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, St Louis, Missouri, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 2 locations

Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma

Phase 1

Terminated

Conditions: Brain and Central Nervous System Tumors
Melanoma
Solid Tumor

Interventions: Drug: PS-341 (VELCADE)
Drug: Temozolomide
Other: immunoenzyme technique

First Posted Date: 2007-08-08

Last Posted Date: 2012-10-02

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 47

Registration Number: NCT00512798

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia

Phase 2

Terminated

Conditions: Dysphagia
Head and Neck Cancer
Mucositis
Xerostomia

Interventions: Behavioral: exercise intervention
Drug: amifostine trihydrate
Procedure: therapeutic dietary intervention

First Posted Date: 2007-07-19

Last Posted Date: 2017-06-20

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 41

Registration Number: NCT00503776

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy